Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Treating Iron Deficiency Anaemia Improves Quality of Life in Patients With Chronic Heart Failure

- Research Highlights Accurate Diagnosis & Treatment has Significant Impact on Quality of Life


News provided by

Vifor Pharma

05 May, 2011, 12:34 GMT

Share this article

Share toX

Share this article

Share toX

BAGSHOT, England, May 5, 2011 /PRNewswire/ -- Over a third (34%)[1,2] of patients with chronic heart failure (CHF) are suffering from associated iron-deficient anaemia (IDA) which is not only exacerbating their condition but is also contributing to a poorer quality of life. In anticipation of European Heart Failure Awareness Day (6 May 2011), Vifor Pharma is taking the opportunity to raise awareness of IDA as a less-recognised and under-managed - yet treatable - side effect of heart failure.

Anaemia is characterised by a low blood count and means that the heart needs to work more efficiently to carry adequate oxygen around the body. Symptoms of anaemia including shortness of breath, fatigue, dizziness and impairment of cognitive function, are similar to those of CHF and as heart failure progresses in patients, so does anaemia. In fact, anaemia complicating heart failure has been shown to be associated with a worse outcome for patients[3] - and in community hospital admissions for heart failure, markers of anaemia were independently associated with an increased risk of death[3].

However, recent research demonstrates that repletion of iron in CHF patients improves cognitive, symptomatic, and exercise performance. The trial, FAIR HF[4] (Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure), which is the largest trial to date ever conducted to study the effects of anaemia in CHF, revealed that:

- 50% of CHF patients treated with Ferinject showed a significant improvement in their quality of life[4]

- Patients receiving Ferinject(R) could walk 39 meters further than at baseline in a 6 minute walk test, compared to approximately 9 meters in the placebo group. The total difference between the patient group treated with Ferinject(R) and the placebo group was 35 meters at week 24[4]

So, in conclusion the study shows that Ferinject is an I.V iron treatment that clearly reduces the day-to-day burden of symptoms such as fatigue, weakness and impaired physical function compared to placebo. However, despite the fact the medical profession accept that anaemia aggravates symptoms in patients with CHF[5], the condition is still frequently under-diagnosed and left untreated.

"There is no doubt that iron-deficient anaemia impacts the quality of life of CHF patients, preventing them from undertaking normal everyday activities such as walking which most people take for granted. Many CHF patients with associated IDA are not being diagnosed and treated efficiently and we are not currently optimising patients' outcome or their quality of life." comments Senthil Vel, Medical Director , Vifor Pharma UK Ltd.

European Heart Failure Awareness Day is a pan-European initiative designed to raise awareness of heart failure, including possible symptoms, the importance of an early and accurate diagnosis as well as receiving optimal treatment.

For full Ferinject(R) Specific Product Characteristics, please visit http://www.medicines.org.uk/EMC/searchresults.aspx?term=ferinject&searchtype=QuickSearch

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

For additional information about Vifor Pharma log onto: viforpharma.com

Notes to editors

About Ferinject(R)

Ferinject(R) is an innovative intravenous iron replacement product discovered and developed by Vifor Pharma. Ferric carboxymaltose, the active pharmaceutical ingredient of Ferinject(R), overcomes the unmet clinical needs of intravenous (I.V.) iron therapy as Ferinject(R) is not associated with dextran-induced hypersensitivity reactions since it is free of dextran and dextran derivatives, and it has a low potential for iron toxicity. Ferinject(R), in doses up to 1000 mg iron, can be administered in a 15 minute infusion in patients with iron deficiency associated with a variety of clinical conditions.

To date, Ferinject(R) has gained marketing authorisation in 30 countries within Europe as well as in South Korea, Argentina and Russia for the treatment of iron deficiency where oral iron is ineffective or cannot be used. In many countries, intravenous iron replacement products are primarily used to treat dialysis patients. However, iron deficiency is also a complication of many other illnesses representing an unmet medical need. Vifor Pharma is evaluating new opportunities in the treatment of iron deficiency with Ferinject(R) in different therapeutic areas. Trials with Ferinject(R) in chronic kidney disease (CKD), oncology (anaemia in cancer patients), gastroenterology (inflammatory bowel diseases) and gynaecology are ongoing or planned.

Vifor Pharma, the Pharma business sector of the Galenica Group, is involved in the discovery, development, manufacture and marketing of pharmaceutical products, with focus on the treatment of iron deficiency, in which Vifor Pharma is one of the leading companies. It also conducts clinical studies for the application of medications for the treatment of various autoimmune diseases. Vifor Pharma also develops and manufactures prescription and over-the-counter (OTC) products, including products developed or sold under license, and markets them internationally. Vifor Pharma is headquartered in Zurich, Switzerland.

References

1. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anaemia in chronic heart failure? American Heart Journal 2004, 147(5):924-30

2. Victor Man-Fai Sim, Michael Chi Yuen Yuen Nam, Steve Riley, Zaheer Yousef, Joanna Hurley, Wai-yee Cheung, Sinead O'Mahony. Anaemia in older people with chronic heart failure: The potential cost. Journal Technology and Health Care Volume 17 Issue 5,6, December 2009

3. A J S Coats. Anaemia and heart failure. Heart. 2004 September; 90(9): 977-979

4. Stefan D. Anker, Josep Comin Colet, Gerasimos Filippatos, Ronnie Willenheimer, Kenneth Dickstein, Helmut Drexler, Thomas F. Lüscher, Boris Bart, Waldemar Banasiak, Joanna Niegowska, Bridget-Anne Kirwan, Claudio Mori, Barbara von Eisenhart Rothe, Stuart J. Pocock, Philip A. Poole-Wilson, Piotr Ponikowski. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361:2436-2448

5. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-61

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.